SpyGlass Pharma Acquires Advanced Vision Science to Advance Drug-Eluting IOL Technology for Glaucoma

SpyGlass Pharma announced on October 1, 2026 that it has acquired Advanced Vision Science (AVS), its existing intraocular lens (IOL) manufacturer, for about $13 million. The deal gives SpyGlass direct control over a key component of its investigational BIM-IOL system, which combines an IOL with sustained delivery of bimatoprost and is in Phase 3 development. The efficacy data reported so far come from an earlier Phase 1/2 study and await confirmation in Phase 3.

Deal Terms

• Acquirer: SpyGlass Pharma
• Target: Advanced Vision Science (AVS), SpyGlass’s existing IOL manufacturer, which also supplies other lens-industry customers
• Price: about $13 million
• Announced: October 1, 2026
• Rationale: direct control over a key component of the Phase 3 BIM-IOL system, with capacity the company says can support commercial scale

How BIM-IOL Works

The system pairs an IOL with sustained release of bimatoprost, a medication used to lower intraocular pressure (IOP). It is designed for patients undergoing cataract surgery who also require IOP management. Glaucoma is a chronic optic neuropathy in which elevated IOP is an important modifiable risk factor. Topical medications remain a major component of treatment, and consistent adherence is challenging for some patients. A drug-delivery implant reduces dependence on daily administration.

Phase 1/2 Results

Company data previously reported for the higher-dose group:

• IOP reduction: mean reduction of approximately 34% from baseline at 12 months in evaluable patients
• Medication status: 98% of evaluable patients free from topical IOP-lowering medications at the assessment point

These figures come from an early, selected cohort and were reported before the acquisition. They carry less weight than a controlled Phase 3 result and do not show that visual-field loss is prevented. Medication-free status also depends on how rescue criteria and follow-up were defined.

Manufacturing and Clinical Questions

A drug-eluting lens is both an implant and a medicine-delivery platform, so consistency of lens manufacture and drug release must hold through scale-up, sterilization and routine cataract workflows. Owning AVS reduces one execution risk. The acquisition may also create opportunities to expand the range of IOL technologies compatible with the platform, and AVS’s work for other customers gives the deal a manufacturing-services dimension beyond BIM-IOL.

Long drug exposure inside an implanted lens raises practical questions about waning delivery, inflammation, lens clarity and the management of pressure that rises after the release period. The pivotal trial should report pressure control against an appropriate comparator, use of additional medication and adverse events over time. Regulatory review and long-term safety evaluation will also be required before widespread clinical adoption.

Conclusion

Owning AVS may reduce manufacturing risk for BIM-IOL, while the early pressure results remain unconfirmed by Phase 3. For surgeons and investors, the central question is whether a cataract-linked drug platform delivers reliable, sustained glaucoma control across ordinary patients after cataract surgery without excessive rescue treatment.

Source: SpyGlass Pharma, SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), 1 October 2026. https://spyglasspharma.gcs-web.com/news-releases/news-release-details/spyglass-pharma-acquires-advanced-vision-science-inc-avs

Source: SpyGlass Pharma, Positive Topline 12-Month Phase 1/2 Results. https://ir.spyglasspharma.com/news-releases/news-release-details/spyglass-pharma-announces-positive-topline-12-month-phase-12

The post SpyGlass Pharma Acquires Advanced Vision Science to Advance Drug-Eluting IOL Technology for Glaucoma appeared first on Ophthalmology Breaking News.

Source: ophthalmologybreakingnews.com
Author: OBN Editorial Team | Date: 2026-10-01 09:00:00